News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
34,402 Results
Type
Article (1301)
Company Profile (3)
Press Release (33098)
Section
Business (15439)
Career Advice (98)
Deals (1947)
Drug Development (3700)
FDA (520)
Job Trends (677)
News (20604)
Policy (1009)
Tag
Academia (46)
Accelerated approval (3)
Adcomms (1)
Allergies (8)
Alliances (1079)
ALS (5)
Alzheimer's disease (86)
Antibody-drug conjugate (ADC) (6)
Approvals (569)
Artificial intelligence (9)
Autoimmune disease (9)
Automation (2)
Bankruptcy (13)
Best Places to Work (659)
BIOSECURE Act (1)
Biosimilars (10)
Biotechnology (3)
Bladder cancer (17)
Breast cancer (39)
Cancer (267)
Cardiovascular disease (24)
Career advice (98)
CAR-T (8)
Cell therapy (16)
Cervical cancer (2)
Clinical research (3399)
Collaboration (44)
Compensation (12)
COVID-19 (65)
CRISPR (3)
C-suite (4)
Cystic fibrosis (4)
Data (486)
Depression (18)
Diabetes (24)
Diagnostics (288)
Digital health (4)
Drug discovery (7)
Drug pricing (3)
Duchenne muscular dystrophy (9)
Earnings (14732)
Editorial (1)
Events (5040)
Executive appointments (13)
FDA (819)
Fibrodysplasia Ossificans Progressiva (3)
Frontotemporal dementia (3)
Funding (25)
Gene editing (4)
Generative AI (2)
Gene therapy (19)
GLP-1 (36)
Government (95)
Guidances (162)
Healthcare (893)
HIV (4)
Huntington's disease (2)
IgA nephropathy (14)
Immunology and inflammation (15)
Immuno-oncology (3)
Indications (14)
Infectious disease (78)
Inflammatory bowel disease (7)
Influenza (3)
Intellectual property (6)
Interviews (9)
IPO (1451)
Job creations (55)
Job search strategy (94)
Labor market (3)
Layoffs (14)
Legal (148)
Liver cancer (4)
Lung cancer (43)
Lymphoma (44)
Manufacturing (15)
MASH (15)
Medical device (808)
Medtech (815)
Mergers & acquisitions (533)
Metabolic disorders (63)
mRNA (2)
Multiple sclerosis (6)
NASH (1)
Neurodegenerative disease (10)
Neuropsychiatric disorders (8)
Neuroscience (153)
NextGen: Class of 2026 (184)
Non-profit (59)
Now hiring (1)
Obesity (25)
Opinion (3)
Ovarian cancer (4)
Pain (9)
Pancreatic cancer (13)
Parkinson's disease (11)
Patents (15)
Patient recruitment (12)
Peanut (2)
People (1070)
Pharmacy benefit managers (1)
Phase 1 (746)
Phase 2 (1402)
Phase 3 (1502)
Pipeline (832)
Policy (2)
Postmarket research (182)
Preclinical (329)
Press Release (1)
Prostate cancer (12)
Psychedelics (4)
Radiopharmaceuticals (5)
Rare diseases (29)
Real estate (145)
Regulatory (940)
Reports (5)
Research institute (45)
Resumes & cover letters (5)
RSV (6)
Schizophrenia (15)
Series A (3)
Sickle cell disease (1)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (3)
Startups (83)
Supply chain (2)
Vaccines (17)
Venture capital (3)
Weight loss (15)
Women's health (7)
Date
Last 7 days (48)
Last 30 days (261)
Last 365 days (2108)
2026 (386)
2025 (2092)
2024 (2309)
2023 (2522)
2022 (2764)
2021 (2908)
2020 (2353)
2019 (1780)
2018 (1322)
2017 (1101)
2016 (786)
2015 (1160)
2014 (737)
2013 (443)
2012 (514)
2011 (556)
2010 (581)
Location
Africa (102)
Alabama (6)
Arizona (17)
Arkansas (1)
Asia (2269)
Australia (271)
California (831)
Canada (219)
China (48)
Colorado (53)
Connecticut (46)
Delaware (34)
Europe (4194)
Florida (109)
Georgia (33)
Illinois (67)
India (2)
Indiana (50)
Japan (34)
Kansas (4)
Kentucky (3)
Louisiana (9)
Maine (7)
Maryland (91)
Massachusetts (498)
Michigan (20)
Minnesota (40)
Mississippi (1)
Missouri (7)
Montana (3)
Nevada (4)
New Hampshire (9)
New Jersey (298)
New Mexico (1)
New York (187)
North Carolina (119)
Northern California (422)
Ohio (18)
Pennsylvania (170)
Puerto Rico (1)
South America (108)
South Carolina (1)
Southern California (321)
Tennessee (10)
Texas (83)
United States (2898)
Utah (29)
Virginia (13)
Washington D.C. (3)
Washington State (81)
Wisconsin (7)
34,402 Results for "104".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status
February 23, 2026
·
3 min read
Press Releases
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
March 3, 2026
·
4 min read
Press Releases
Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
February 12, 2026
·
12 min read
Press Releases
Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy
December 15, 2025
·
7 min read
Press Releases
EvolveImmune Therapeutics Announces Initiation of Dosing in a Phase 1 Trial of EVOLVE104 in Patients with Solid Tumors
December 16, 2025
·
3 min read
Press Releases
Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting
January 20, 2026
·
5 min read
Press Releases
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer’s Disease Therapy
December 16, 2025
·
2 min read
Press Releases
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
October 13, 2025
·
8 min read
Press Releases
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
November 14, 2025
·
5 min read
pipeline
Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
February 5, 2026
·
2 min read
·
Tristan Manalac
1 of 3,441
Next
